Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Agnieszka Skoczylas.
PLOS ONE | 2017
Elzbieta Radzikowska; Elżbieta Wiatr; Renata Langfort; Iwona Bestry; Agnieszka Skoczylas; Ewa Szczepulska-Wójcik; Dariusz Gawryluk; Piotr Rudzinski; Joanna Chorostowska-Wynimko; Kazimierz Roszkowski-Śliż
Background Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown origin. Corticosteroids are the standard treatment, but clarithromycin (CAM) is also effective. The aim of this observational retrospective study was to compare the results of CAM versus prednisone (PRE) treatment in patients with biopsy-proven OP without respiratory insufficiency. Material and methods In a 15-year period, 40 patients were treated with CAM (500 mg twice daily orally for 3 months) and 22 with PRE (mean initial dose of 0.67 ± 0.24 mg/kg/d for a mean of 8.59 ± 3.05 months). Results The clinical presentation, laboratory, and radiological findings did not differ markedly between patients treated with CAM and PRE, with the exception of a higher frequency of sweats (55% vs. 23%; p < 0.015), ground glass opacities (95% vs. 50%; p <0.0001) and nodular lesions (45% vs. 18%; p = 0.036) in the CAM group. A complete response was achieved in 35(88%) patients treated with CAM and in all treated with PRE. Patients treated with PRE relapsed more frequently than those treated with CAM (54.5% vs. 10%; p < 0.0001). Corticosteroid-related adverse events were noticed in 8(6.5%) patients (with one death), but CAM caused only one (2.5%) allergic reaction. A FVC >80% identified patients who might be successfully treated with CAM with a sensitivity of 60% and a specificity of 88.57% (AUC 0.869; 95% CI 0.684–1; p = 0.008); the figures for the FEV1 were >70%, a sensitivity of 60%, and a specificity of 91.43% (AUC 0.809; 95%CI 0.609–1; p = 0.027). Conclusions CAM can be used to treat COP patients in whom the pulmonary function parameters are within normal limits. Such therapy is shorter, better tolerated, and associated with fewer adverse events and relapses than is PRE. However, the therapy is ineffective in some patients.
Pneumonologia i Alergologia Polska | 2016
Monika Szturmowicz; Aneta Kacprzak; Barbara Burakowska; Agnieszka Skoczylas; Iwona Bestry; Jan Kuś; Anna Fijałkowska; Adam Torbicki; Marcin Kurzyna
INTRODUCTION Inhomogeneity of lung attenuation pattern is observed in high resolution chest computed tomography (HRCT) in some IPAH patients despite lack of interstitial lung disease. Such radiological changes are described either as ill-defined centrilobular nodules (CN) or as focal ground glass opacities (FGGO). There is no consensus in the literature, whether they indicate the distinct type of IPAH, or pulmonary venoocclusive disease (PVOD) with subtle radiological changes. Thus the aim of the present pilot study was to assess the frequency and clinical significance of inhomogenic lung attenuation pattern in IPAH. MATERIAL AND METHODS 52 IPAH patients (38 females, 14 males, mean age 41 years ± 15 years), entered the study. All available chest CT scans were reviewed retrospectively by the experienced radiologist, not aware about the clinical data of the patients. RESULTS CN were found in 10 patients (19%), FGGO - in 12 patients (23%). No lymphadenopathy or interlobular septal thickening suggestive of PVOD were found. The significant differences between CN and the remaining patients included: lower mean age - 31 and 43.5 years, (p = 0.02), lack of persistent foramen ovale (PFO) - 0% and 43% (p = 0.03), and higher mean right atrial pressure (mRAP) - 12.5 mm Hg and 7.94 mm Hg (p = 0.01). No significant survival differences were observed between the groups of CN, FGGO and the remaining patients. CONCLUSION Centrilobular nodules in IPAH were combined with lack of PFO, higher mRAP and younger age of patients.
Advances in respiratory medicine | 2010
Anna Stokłosa; Agnieszka Skoczylas; Anna Rudnicka; Michal Bednarek; Krystian Krzyżanowski; Dorota Górecka
Advances in respiratory medicine | 2007
Agnieszka Skoczylas; Paweł Śliwiński
Advances in respiratory medicine | 2010
Monika Czystowska; Anna Stokłosa; Ewa Szczepulska-Wójcik; Krystyna Maszkowska-Kopij; Lucyna Opoka; Agnieszka Skoczylas; Dorota Górecka
Advances in respiratory medicine | 2010
Monika Czystowska; Agnieszka Skoczylas; Anna Rudnicka; Barbara Kazanecka; Robert Pływaczewski; Paweł Śliwiński; Dorota Górecka
Pneumonologia i Alergologia Polska | 2009
Robert Pływaczewski; Monika Czystowska; Agnieszka Skoczylas; Przemyslaw Bielen; Luiza Jonczak; Dorota Górecka; Paweł Śliwiński
Advances in respiratory medicine | 2009
Robert Pływaczewski; Monika Czystowska; Agnieszka Skoczylas; Przemyslaw Bielen; Luiza Jonczak; Dorota Górecka; Paweł Śliwiński
Journal of Ultrasonography | 2018
Natalia Buda; Wojciech Kosiak; Elzbieta Radzikowska; Robert Olszewski; Ewa Jassem; Elżbieta Magdalena Grabczak; Andrzej Pomiećko; Jakub PiotrkowskI; Maciej Piskunowicz; Malwina Sołtysiak; Szymon Skoczyński; Grzegorz Jaczewski; Jolanta Odrowska; Agnieszka Skoczylas; Marcin Wełnicki; Jakub Wiśniewski; Anna Zamojska
European Respiratory Journal | 2017
Anna Goljan Geremek; Monika Czystowska; Agnieszka Skoczylas; Urszula Demkow; Elzbieta Puscinska; Michal Bednarek; Adam Nowinski; Pawel Sliwinski